Given that 500 μM PA may be more relevant to the clinical concentration of FFAs in patients with atherosclerosis and diabetes, it is assumed that A-FABP may be increased in atherosclerosis and diabetes patients, and this warrants further study. This evidence concerns the gene FABP4 and diabetes mellitus.